These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 14979612)

  • 1. In vitro activity of stampidine against primary clinical human immunodeficiency virus isolates.
    Uckun FM; Pendergrass S; Qazi S; Venkatachalam TK
    Arzneimittelforschung; 2004; 54(1):69-77. PubMed ID: 14979612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potency of stampidine against multi-nucleoside reverse transcriptase inhibitor resistant human immunodeficiency viruses.
    Uckun FM; Venkatachalam TK; Qazi S
    Arzneimittelforschung; 2006 Feb; 56(2A):193-203. PubMed ID: 16570827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stampidine as a novel nucleoside reverse transcriptase inhibit with potent anti-HIV activity.
    Uckun FM
    Arzneimittelforschung; 2006 Feb; 56(2A):121-35. PubMed ID: 16570821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-retroviral activity of GMP-grade stampidine against genotypically and phenotypically nucleoside reverse transcriptase inhibitor resistant recombinant human immunodeficiency virus. An in vitro study.
    Uckun FM; DuMez D; Qazi S; Tibbles H; Venkatachalam TK
    Arzneimittelforschung; 2007; 57(2):112-21. PubMed ID: 17396622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro anti-HIV potency of stampidine alone and in combination with standard anti-HIV drugs.
    Uckun FM; Qazi S; Venkatachalam TK
    Arzneimittelforschung; 2005; 55(4):223-31. PubMed ID: 15901046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stampidine is a potent inhibitor of Zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations.
    Uckun FM; Pendergrass S; Venkatachalam TK; Qazi S; Richman D
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3613-6. PubMed ID: 12384373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stampidine as a promising antiretroviral drug candidate for pre-exposure prophylaxis against sexually transmitted HIV/AIDS.
    Uckun FM; Cahn P; Qazi S; D'Cruz O
    Expert Opin Investig Drugs; 2012 Apr; 21(4):489-500. PubMed ID: 22360744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo toxicity, pharmacokinetics, and anti-human immunodeficiency virus activity of stavudine-5'-(p-bromophenyl methoxyalaninyl phosphate) (stampidine) in mice.
    Uckun FM; Qazi S; Pendergrass S; Lisowski E; Waurzyniak B; Chen CL; Venkatachalam TK
    Antimicrob Agents Chemother; 2002 Nov; 46(11):3428-36. PubMed ID: 12384347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N'-[2-(2-thiophene) ethyl]-N'-[2-(5-bromopyridyl)]thiourea (HI-443), a rationally designed non-nucleoside reverse transcriptase inhibitor compound with potent anti-HIV activity.
    Uckun FM; Qazi S; Venkatachalam T
    Arzneimittelforschung; 2007; 57(5):278-85. PubMed ID: 17598700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenyl phosphoramidate derivatives of stavudine as anti-HIV agents with potent and selective in-vitro antiviral activity against adenovirus.
    Uckun FM; Pendergrass S; Qazi S; Samuel P; Venkatachalam TK
    Eur J Med Chem; 2004 Mar; 39(3):225-34. PubMed ID: 15051170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
    Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unmet challenges in HIV therapy and potential of stampidine.
    Uckun FM
    Arzneimittelforschung; 2006 Feb; 56(2A):117-20. PubMed ID: 16570820
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial.
    Calvez V; Costagliola D; Descamps D; Yvon A; Collin G; Cécile A; Delaugerre C; Damond F; Marcelin AG; Matheron S; Simon A; Valantin MA; Katlama C; Brun-Vézinet F
    Antivir Ther; 2002 Sep; 7(3):211-8. PubMed ID: 12487389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates.
    Duan C; Poticha D; Stoeckli TC; Petropoulos CJ; Whitcomb JM; McHenry CS; Kuritzkes DR
    J Infect Dis; 2001 Nov; 184(10):1336-40. PubMed ID: 11679926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.
    Paolucci S; Baldanti F; Campanini G; Cancio R; Belfiore A; Maga G; Gerna G
    Antiviral Res; 2007 Nov; 76(2):99-103. PubMed ID: 17640745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microbicides for multidrug-resistant and multitropic HIV-1.
    D'Cruz OJ; Uckun FM
    Curr Opin Investig Drugs; 2008 Feb; 9(2):152-69. PubMed ID: 18246518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stampidine: a selective oculo-genital microbicide.
    D'Cruz OJ; Uckun FM
    J Antimicrob Chemother; 2005 Jul; 56(1):10-9. PubMed ID: 15919769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure.
    Rusconi S; De Pasquale MP; Milazzo L; Kurtagic S; Bulgheroni E; Citterio P; Galazzi M; La Seta Catamancio S; Galli M
    Antivir Ther; 1998; 3(4):203-7. PubMed ID: 10682139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
    Miller V; Larder BA
    Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo pharmacokinetics and toxicity profile of the anti-HIV agent stampidine in dogs and feline immunodeficiency virus-infected cats.
    Uckun FM; Waurzyniak B; Tibbles H; Venkatachalam TK; Erbeck D
    Arzneimittelforschung; 2006 Feb; 56(2A):176-92. PubMed ID: 16570826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.